Erratum to: Assessing the safety and efficacy of ruxolitinib in a multicenter, open-label study in Japanese patients with myelofibrosis

Springer Science and Business Media LLC - Tập 105 - Trang 387-387 - 2017
Norio Komatsu1, Keita Kirito2, Kazuya Shimoda3, Takayuki Ishikawa4, Kohshi Ohishi5, Kazuma Ohyashiki6, Naoto Takahashi7, Hikaru Okada8, Taro Amagasaki8, Toshio Yonezu8, Koichi Akashi9
1Department of Hematology, Juntendo University School of Medicine, Juntendo University, Tokyo, Japan
2Department of Hematology and Oncology, University of Yamanashi, Yamanashi, Japan
3Department of Gastroenterology and Hematology, University of Miyazaki, Miyazaki, Japan
4Department of Hematology, Kobe City Medical Center General Hospital, Kobe, Japan
5Blood Transfusion Service, Mie University, Tsu, Japan
6Department of Hematology, Tokyo Medical University, Tokyo, Japan
7Department of Hematology, Nephrology, and Rheumatology, Akita University Graduate School of Medicine, Akita, Japan
8Novartis Pharma KK, Tokyo, Japan
9Department of Medicine and Biosystemic Science, Kyushu University, Fukuoka, Japan

Thông tin
Thông tin xuất bản

Springer Science and Business Media LLC

Tập 105

387-387

Thông tin tác giả